Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2020 / N 4

Уридин и уридинсодержащие комплексы при неспецифической боли в спине. От патогенеза к лечению
Д.А. Искра, Д.Ю. Бутко

References

1. Florián J, Leszczyński J. Spontaneous DNA mutations induced by proton transfer in the guanine-cytosine base pairs: an energetic perspective. Journal of the American Chemical Society 1996 Mar;118(12):3010-7.
2. Harden TK, Sesma JI, Fricks IP, Lazarowski ER, Harden TK. Signalling and pharmacological properties of the P2Y receptor. Acta Physiologica (Oxford, England) 2010 Jun;199(2):149-60.
3. Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, Handschumacher RE. Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochimica et Biophysica Acta 2002 Jul;1587(2-3):133-44.
4. Martin DS, Stolfi RL, Sawyer RC. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemotherapy and Pharmacology 1989;24(1):9-14.
5. Traut TW. Physiological concentrations of purines and pyrimidines. Molecular and Cell Biochemistry 1994 Nov;140(1):1-22.
6. Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain Research Reviews 2006 Sep;52(2):389-97.
7. Jacobson KA, Boeynaems JM. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discovery Today 2010 Jul;15(13-14):570-8.
8. Ulrich H, Abbracchio MP, Burnstock G. Extrinsic purinergic regulation of neural stem/ progenitor cells: implications for CNS development and repair. Stem Cell Reviews and Reports 2012 Sep;8(3):755-67.
9. Agnati LF, Fuxe K, Ruggeri M, Pich EM, Benfenati F, Volterra V, Ungerstedt U, Zini I. Effects of chronic treatment with uridine on striatal dopamine release and dopamine related behaviours in the absence or the presence of chronic treatment with haloperidol. Neurochemistry International 1989;15(1):107-13.
10. Choi JW, Shin CY, Choi MS, Yoon SY, Ryu JH, Lee JC, Kim WK, El Kouni MH, Ko KH. Uridine protects cortical neurons from glucose deprivation-induced death: possible role of uridine phosphorylase. Journal of Neurotrauma 2008 Jun;25(6):695-707.
11. Connolly GP, Simmonds HA, Duley JA. Pyrimidines and CNS regulation. Trends in Pharmacological Sciences 1996 Mar;17(3):106-7.
12. Peters GJ, van Groeningen CJ, Laurensse EJ, Lankelma J, Leyva A, Pinedo HM. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemotherapy and Pharmacology 1987;20(2):101-8.
13. Peters GJ, van Groeningen CJ, Laurensse E, Kraal I, Leyva A, Lankelma J, Pinedo HM. Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. Pharmaceutical Research 1987 Apr;4(2):113-9.
14. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CAF, Bongers A, Harrison J, Swinkels SHN, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJGH. The efficacy of souvenaid in mild Alzheimer’s disease: a randomized, controlled, double-blind, parallel group, multi-centre, multi-country clinical trial. Journal of Alzheimer’s Disease 2012;31(1):225-36.
15. Beamer E, Gölöncsér F, Horváth G, Bekő K, Otrokocsi L, Koványi B, Sperlágh B. Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. Neuropharmacology 2016;104:94-104.
16. Kobayashi K, Yamanaka H, Yanamoto F, Okubo M, Noguchi K. Multiple P2Y sub- types in spinal microglia are involved in neuropathic pain after peripheral nerve injury. Glia 2012 Oct;60(10):1529-39.
17. Weisman GA, Woods LT, Erb L, Seye CI. P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential. CNS & Neurological Disorders Drug Targets 2012 Sep;11(6):722-38.
18. Lecona E, Turnay J, Nieves O, Guzmán-Aránguez A, Morgan RO, Fernandez MP, Lizarbe MA. Structural and functional characterization of recombinant mouse annexin A11: influence of calcium binding. The Biochemical Journal 2003 Jul;373(Pt 2):437-49.
19. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C, Jacobson KA, Weisman GA, Burnstock G. Characterization of the UDP-glucose receptor (re-named here the P2Y 14 receptor) adds diversity to the P2Y receptor family. Trends in Pharmacological Sciences 2003 Feb;24(2):52-5.
20. Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P, McMillan L, Trill J, Swift A, Aiyar N, Taylor P, Vawter L, Naheed S, Szekeres P, Hervieu G, Scott C, Watson JM, Murphy AJ, Duzic E, Klein C, Bergsma DJ, Wilson S, Livi GP. AG protein-coupled receptor for UDP-glucose. The Journal of Biological Chemistry 2000 Apr;275(15):10767-71.
21. Endo Y, Isono K, Kondo M, Tamaoki J, Nagai A. Interleukin-9 and Interleukin-13 augment UTP-induced Cl ion transport via hCLCA1 expression in a human bronchial epithelial cell line. Clinical & Experimental Allergy 2007 Feb;37(2):219-24.
22. Kobayashi D, Ohkubo S, Nakahata N. Contribution of extracellular signal-regulated kinase to UTP-induced interleukin-6 biosynthesis in HaCaT keratinocytes. Journal of Pharmacological Sciences 2006 Dec;102(4):368-76.
23. Zhang Z, Wang Z, Ren H, Yue M, Huang K, Gu H, Liu M, Du B, Qian M. P2Y6 agonist uridine 5′-diphosphate promotes host defense against bacterial infection via monocyte chemoattractant protein-1-mediated monocytes/macrophages recruitment. The Journal of Immunology (Baltimore, Md.: 1950) 2011 May;186(9):5376-87.
24. Yakupov EZ. Adjuvant therapy of pain syndromes: prospects of using nucleotides. SS Korsakov Journal of Neurology and Psychiatry 2019;119(10):141-5 (In Russian).
25. Mibielli MA, Nunes CP, Cohen JC, Júnior ABS, Higashi R, Bendavit GG, Oliveira L, Geller M. Treament of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxocobalamin. Proceedings of the Western Pharmacology Society 2010;53:5-12.
26. Mibielli MA, Nunes CP, Scussel AB Jr, Neto MS, Oliveira L, Geller M. Symptomatic improvement in an acute, non-traumatic spine pain model with a combination of uridine triphosphate, cytidine monophosphate, and hydroxocobalamin. Pain Studies and Treatment 2014 Jan;2(1):6-10.
27. Goldberg H, Scussel AR Jr, Cohen JC, Rzetelna H, Nunes FP, Mezitis SGE, Ozeri DJ, Daher JPL, Nunes SP, Oliveira L, Geller M. Neural compression-induced neuralgias: clinical evaluation of the effect of nucleotides associated with vitamin B12. Revista Brasileira de Medicina 2009;66(11):380-5.
28. Goldberg H, Mibielli MA, Nunes CP, Goldberg SW, Buchman L, Mezitis SGE, Rzetelna H, Oliveira L, Geller M, Wajnsztajn F. A double-blind, randomized, comparative study of the use of a combination of uridine tri- phosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. Journal of Pain Research 2017;10:397-404.
29. Naslausky Mibielli MA, Nunes CP, Goldberg H, Buchman L, Oliveira L, Mezitis SGE, Wajnzstajn F, Kaufman R, Nigri R, Cytrynbaum N, Cunha KS, Santos A, Goldberg SW, Platenik NC, Rzetelna H, Bertoluci Futuro D, de Souza Da Fonseca A, Geller M. Nucleotides cytidine and uridine associated with vitamin B12 vs B-complex vitamins in the treatment of low back pain: the NUBES study. Journal of Pain Research 2020 Oct;13:2531-41.
30. Yakupov EZ, Troshina YuV, Kashapova AO, Nasryeva AM, Chizh RS. Results of an open observational study on multimodal effect efficacy and safety of supplement neurouridine in patients with nonspecific low back pain (MULTINEURO-1). SS Korsakov Journal of Neurology and Psychiatry 2020;120(9):53-9 (In Russian).
31. Yamamoto T, Koyama H, Kurajoh M, Shoji T, Tsutsumi Z, Moriwaki Y. Biochemistry of uridine in plasma. Clinica Chimica Acta 2011 Sep;412(19-20):1712-24.
32. Quesada I, Tudurí E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. The Journal of Endocrinology 2008 Oct;199(1):5-19.
33. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Ohata H, Yamakita J, Nakamo T, Higashino K. Effect of amino acids on the plasma concentration and urinary excretion of uric acid and uridine. Metabolism 1999 Aug;48(8):1023-7.
34. Gomez-Angelats M, del Santo B, Mercader J, Ferrer-Martinez A, Felipe A, Casado J, Pastor-Anglada M. Hormonal regulation of concentrative nucleoside transport in liver parenchymal cells. The Biochemical Journal 1996 Feb;313(Pt 3):915-20.
35. Zhao X, Xu M, Jorgenson K, Kong J. Neurochemical changes in patients with chronic low back pain detected by proton magnetic resonance spectroscopy: a systematic review. NeuroImage. Clinical 2017 Nov;13:33-8.
36. Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A systematic review of dextrose prolotherapy for chronic musculoskeletal pain. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2016 Jul;9:139-59.
37. Ahlawat A, Sharma S. A new promising simultaneous approach for attenuating type II diabetes mellitus induced neuropathic pain in rats: iNOS inhibition and neuroregeneration. European Journal of Pharmacology 2018 Jan;818:419-28.
38. Kanat O, Bagdas D, Ozboluk HY, Gurun MS. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. Journal of B.U.ON 2013 Oct-Dec;18(4):1012-8.
39. Rowley TJ, McKinstry A, Greenidge E, Smith W, Flood P. Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative pain. British Journal of Anaesthesia 2010 Aug;105(2):201-7.
40. Sidhu N, Davies S, Nadarajah A, Rivera J, Whittington R, Mercier RJ, Virag L, Wang S, Flood P. Oral choline supplementation for postoperative pain. British Journal of Anaesthesia 2013 Aug;111(2):249-55.
41. Caner B, Kafa MI, Bekar A, Kurt MA, Karli N, Cansev M, Ulus IH. Intraperitoneal administration of CDP-choline or a combination of cytidine plus choline improves nerve regeneration and functional recovery in a rat model of sciatic nerve injury. Neurological Research 2012 Apr;34(3):238-45.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]